Committed Investment: August, 2022
Status: Active Portfolio Company
SpayVac’s (Madison) revolutionary drug release technology allows for successful sterilization of animals with only a single injection. Originally developed by a Canadian company for other applications, the SpayVac team brings its unique experience and industry connections to re-focusing the intellectual property on the animal health market, initially targeting the feral animal mitigation market.
The company already has contracts all over the world to address feral horses and deer and have received inquiries on pigs, fish, primates, and even cats and dogs. The company anticipates expanding from the feral market to companion animals, eventually eliminating the need for surgical procedures for household pets.